Abbott Laboratories
$112.47+0.8%YTD-10.8%1Y-15.1%
Mentions · last 7 days
181+2%
Price updated 2d ago·X counts updated 7d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $ABT, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Devices sits in its cycle right now — and what that implies for $ABT.
Medical - Devices
Elective procedure volume recovery and aging-demographic demand are the structural drivers; robotic surgery adoption (ISRG) and GLP-1-driven procedure mix shifts are the near-term dynamics. Hospital capex cycles determine device upgrade timing — CapEx returning after COVID deferral.
What this means for $ABT
Partial — medical device revenue depends on elective procedure volumes and hospital capex; Abbott Laboratories, along with its affiliated entities, is a global healthcare .
Industry benchmark
25-name peer basket
+8.5%YTD
+27.8%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
25.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
6.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
18.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
4.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
3.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
12.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
56.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Jul 16, 2026$1.31$1.28+2.3%
Q1 2026Apr 16, 2026$1.15$1.14+0.9%
Q4 2025Jan 22, 2026$1.50$1.500.0%
Q3 2025Oct 15, 2025$1.30$1.300.0%
Next earningsWed, Oct 21·consensus EPS $1.43
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$11.2B+7.8%56.3%16.5%$0.62$916.0M
Q4 FY25$11.5B+4.4%57.0%19.6%$1.02$2.6B
Q3 FY25$11.4B+6.9%55.7%18.1%$0.94$2.3B
Q2 FY25$11.1B+7.4%56.4%18.4%$1.02$1.5B
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$50.3B$49.0B – $50.6B$5.52$5.47 – $5.5520
FY27$54.7B$53.6B – $55.3B$6.06$6.00 – $6.1820
FY28$58.5B$53.7B – $59.5B$6.72$4.50 – $8.0620
FY29$62.9B$61.1B – $63.6B$7.45$7.19 – $7.5611
FY30$67.2B$65.4B – $68.0B$8.28$7.98 – $8.4011
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.55%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+5.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMega float · 1.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.585-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KPress release / Reg FDAug 208-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary
3New insider — initial holdingsApr 283
AI summary
8-KOfficer or director changeApr 278-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary
8-KMaterial agreementMar 98-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
+ 15 other (2 10-Qs · 2 earnings 8-Ks · 2 13Gs · 2 S-8s) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
27,113 Shares in Abbott Laboratories $ABT Acquired by Frazier Financial Advisors LLCCM Wealth Advisors LLC Invests $1.08 Million in Abbott Laboratories $ABTBlackRock Inc. Raises Stock Position in Abbott Laboratories $ABTWhy Abbott (ABT) is a Top Momentum Stock for the Long-TermAMG National Trust Bank Has $2.86 Million Holdings in Abbott Laboratories $ABT
More in Medical - Devices
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 11 · last 7 days